Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Astria Therapeutics Inc (ATXS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/13/2025: ATXS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 92.2% | Avg. Invested days 48 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 06/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 322.80M USD | Price to earnings Ratio - | 1Y Target Price 28.67 |
Price to earnings Ratio - | 1Y Target Price 28.67 | ||
Volume (30-day avg) 539236 | Beta 0.38 | 52 Weeks Range 3.56 - 12.92 | Updated Date 06/15/2025 |
52 Weeks Range 3.56 - 12.92 | Updated Date 06/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.88 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -22.56% | Return on Equity (TTM) -32.89% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 128126732 | Price to Sales(TTM) - |
Enterprise Value 128126732 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -7.57 | Shares Outstanding 56434200 | Shares Floating 33012325 |
Shares Outstanding 56434200 | Shares Floating 33012325 | ||
Percent Insiders 0.49 | Percent Institutions 104.13 |
Analyst Ratings
Rating 4.78 | Target Price 28.67 | Buy 2 | Strong Buy 7 |
Buy 2 | Strong Buy 7 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Astria Therapeutics Inc
Company Overview
History and Background
Astria Therapeutics, Inc., formerly Integral Molecular, was founded to develop therapies for rare and life-threatening allergic and immunological diseases. They focus on transformative therapies for hereditary angioedema (HAE) and other related conditions.
Core Business Areas
- Hereditary Angioedema (HAE) Therapeutics: Development and commercialization of STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, for the treatment of HAE attacks. Also, developing STAR-1811, a potential next-generation long-acting monoclonal antibody for HAE prophylaxis.
Leadership and Structure
The leadership team includes Jill C. Milne, Ph.D. as Chief Executive Officer, and other executives in research, development, and finance. The company operates with a structure typical of a biotechnology firm, focusing on research and clinical development.
Top Products and Market Share
Key Offerings
- STAR-0215: A monoclonal antibody inhibitor of plasma kallikrein under development for the treatment of HAE attacks. Market share is currently 0% as it is still in clinical trials. Competitors include Takeda (TAK) with Takhzyro, CSL Behring with Berinert and Haegarda, and BioCryst Pharmaceuticals (BCRX) with Orladeyo.
- STAR-1811: A next-generation long-acting monoclonal antibody for HAE prophylaxis. Market share is currently 0% as it is still in development. Competitors include Takeda (TAK) with Takhzyro, CSL Behring with Berinert and Haegarda, and BioCryst Pharmaceuticals (BCRX) with Orladeyo.
Market Dynamics
Industry Overview
The biopharmaceutical industry, specifically the market for rare disease treatments like HAE, is characterized by high unmet medical needs, significant regulatory hurdles, and potential for high returns on successful therapies. Competition is intense.
Positioning
Astria Therapeutics is positioned as an emerging player focusing on novel HAE therapies. Their competitive advantage relies on their potentially differentiated monoclonal antibody approach and long-acting profile.
Total Addressable Market (TAM)
The global HAE market is expected to reach several billion dollars by the end of the decade. Astria is positioned to capture a portion of this TAM, dependent on clinical trial success and market access.
Upturn SWOT Analysis
Strengths
- Novel monoclonal antibody approach
- Potential for long-acting HAE prophylaxis
- Experienced management team
- Strong focus on HAE market
Weaknesses
- Clinical trial risks
- Dependence on successful development of STAR-0215 and STAR-1811
- Limited product pipeline
- No currently marketed products
Opportunities
- High unmet need in HAE treatment
- Potential for premium pricing of innovative therapies
- Partnerships and collaborations
- Expansion into other rare disease areas
Threats
- Competition from established HAE therapies
- Regulatory hurdles and approval timelines
- Pricing pressures from payers
- Clinical trial failures
Competitors and Market Share
Key Competitors
- TAK
- CSL
- BCRX
Competitive Landscape
Astria Therapeutics is at a disadvantage compared to established players with marketed products. Its success hinges on demonstrating superior efficacy and convenience with its novel therapies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's early stage. Growth is primarily reflected in R&D spending and preclinical data.
Future Projections: Future growth is dependent on successful clinical trials and potential regulatory approvals for STAR-0215 and STAR-1811. Analyst estimates are unavailable but suggest increasing value if milestones are achieved.
Recent Initiatives: Recent initiatives include advancing STAR-0215 through clinical trials and developing STAR-1811.
Summary
Astria Therapeutics is a high-risk, high-reward biotechnology company focused on developing innovative therapies for hereditary angioedema. The company's success hinges on the successful completion of clinical trials for its lead compounds. The company faces intense competition from established players in the HAE market. Successfully navigating regulatory hurdles and securing market access will be critical for long-term growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Market share data is estimated based on available information and may not be precise. Forward-looking statements involve risks and uncertainties.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Astria Therapeutics Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2015-06-25 | Co-Founder, CEO, President & Director Ms. Jill C. Milne Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 78 | Website https://www.astriatx.com |
Full time employees 78 | Website https://www.astriatx.com | ||
Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.